Alnylam Pharmaceuticals Inc (ALNY)vsCanton Strategic Holdings, Inc. (CNTN)
ALNY
Alnylam Pharmaceuticals Inc
$205.48
-28.31%
HEALTHCARE · Cap: $35.71B
CNTN
Canton Strategic Holdings, Inc.
$1.85
-4.15%
HEALTHCARE · Cap: $157.33M
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
CNTN
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.2%
Fair Value
$2337.47
Current Price
$205.48
$2131.99 discount
Intrinsic value data unavailable for CNTN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 25.5x book value
0.0% revenue growth
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.49 suggests the stock is reasonably priced for its growth.
Bull Case : CNTN
The strongest argument for CNTN centers on Price/Book.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 67.0x leaves little room for execution misses.
Bear Case : CNTN
The primary concerns for CNTN are Revenue Growth, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
ALNY profiles as a growth stock while CNTN is a value play — different risk/reward profiles.
CNTN carries more volatility with a beta of 1.44 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 27/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Canton Strategic Holdings, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Canton Strategic Holdings, Inc. (CNTN) operates as a diversified investment firm focused on maximizing shareholder value through strategic acquisitions and the management of a diverse asset portfolio across multiple sectors. With an emphasis on value-driven investments and operational efficiencies, CNTN is strategically positioned to leverage emerging market opportunities and propel sustainable growth. The company’s robust approach to strategic planning and investment execution aims to deliver superior returns while effectively navigating the complexities of the financial landscape, making it an attractive option for institutional investors seeking stability and growth potential.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?